Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger

Dermatofibrosarcoma Protuberans Clinical Trial

Official title:
Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger

Status Completed

Clinical Trial Summary

The purpose of this proposed study is to assess effectiveness of MOHS micrographic surgery as a form of treatment for dermatofibrosarcoma protuberans in patients who are 10 years of age or younger through review of the patients at Mayo Clinic treated from 1988-2017, and to explore the challenges that providers face which may prevent them performing this potentially superior treatment. This study will provide a comparison of outcomes and recurrence rates in pediatric patients treated by MOHS versus traditional excision.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03381846
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Completed
Phase	N/A
Start date	July 1, 2018
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00243191` - Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans	Phase 2
Completed	`NCT00084630` - Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans	Phase 2
Completed	`NCT01154452` - Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Phase 1/Phase 2
Completed	`NCT00720174` - Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma	Phase 1
Completed	`NCT00346164` - Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma	Phase 3
Completed	`NCT00659360` - AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma	Phase 2